Clinical Trial Update: Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating baricitinib for steroid-resistant/relapse immune thrombocytopenia (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: ITP, Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN